Biogen/UCB’s Lupus Drug Shows Consistent Efficacy Across Endpoints, Over Time
Second Phase III Trial To Begin This Year
Detailed results for CD40L inhibitor dapirolizumab pegol showed consistent improvements over time with meaningful gains over placebo across all endpoints in its first Phase III study.
